Tag: 200-300

On July 24, 1995, Kelly, T. Ross; Lang, Fengrui published an article.Quality Control of Methyl 6-bromo-5-methoxypicolinate The title of the article was Total synthesis of dimethyl sulfomycinamate. And the article contained the following:

The first total synthesis of di-Me sulfomycinamate is described. Highlights of the synthesis include a selective palladium-catalyzed coupling reaction on a bromo triflate, and a condensation reaction to form the oxazole ring. The experimental process involved the reaction of Methyl 6-bromo-5-methoxypicolinate(cas: 170235-18-4).Quality Control of Methyl 6-bromo-5-methoxypicolinate

The Article related to sulfomycinamate total synthesis, Biomolecules and Their Synthetic Analogs: Other Bacterial and Fungal Metabolites and other aspects.Quality Control of Methyl 6-bromo-5-methoxypicolinate

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Fernandez-Salas, Jose A.; Manzini, Simone; Piola, Lorenzo; Slawin, Alexandra M. Z.; Nolan, Steven P. published an article in 2014, the title of the article was Ruthenium catalysed C-H bond borylation.Synthetic Route of 1349171-28-3 And the article contains the following content:

An easily prepared series of phenylindenyldihydridosilyl ruthenium complexes (2a-2d) was obtained by reaction of tertiary silanes with the com.-available [RuCl(3-phenylindenyl)(PPh3)2] (1). The [RuH2(3-phenylindenyl)(SiEt3)] (2a) complex was shown to be highly efficient (1.5 mol%) in the ortho-selective borylation of pyridyl substrates, with yields of up to 90%. A novel ruthenium(IV)-catalyzed C-H activation borylation/functionalization reaction using a remarkably low catalyst loadings is described. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Synthetic Route of 1349171-28-3

The Article related to phenylindenyldihydridosilyl ruthenium complex preparation catalyst borylation, Organometallic and Organometalloidal Compounds: Group Viii – Co, Ni, Ru, Rh, Pd, Os, Ir, Pt and other aspects.Synthetic Route of 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 22, 2014, Magda, Darren; Xu, Jide; Butlin, Nathaniel G. published a patent.Product Details of 170235-18-4 The title of the patent was Preparation of di-macrocycles and their complexes for use in therapeutics and diagnostic applications. And the patent contained the following:

The invention relates to chem. compounds of formula I and complexes that can be used in therapeutic and diagnostic applications. Compounds of formula I wherein B1, B2, B3 and B4 are independently N, C, B, Si and P; F1 and F2 are independently H, (un)substituted alkyl, (un)substituted heteroaryl, (un)substituted aryl, etc.; L1 – L9 are independently (un)substituted alkyl, (un)substituted heteroalkyl, (un)substituted aryl, etc.; A1, A2, A3 and A4 are independently substituted aryl and (un)substituted heteroaryl; are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their metal chelation ability for use in therapeutic and diagnostic application (some data given). The experimental process involved the reaction of Methyl 6-bromo-5-methoxypicolinate(cas: 170235-18-4).Product Details of 170235-18-4

The Article related to dimacrocycle preparation complex therapeutic and diagnostic application, Heterocyclic Compounds (More Than One Hetero Atom): Eight- and Higher-Membered Rings and other aspects.Product Details of 170235-18-4

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On May 17, 2018, Tsai, Jui-Yi; Xia, Chuanjun; Lin, Chun; Palacios, Adrian U.; Onate, Enrique; Esteruelas, Miguel A.; Boudreault, Pierre-Luc T.; Bajo, Sonia; Olivan, Montserrat published a patent.HPLC of Formula: 1349171-28-3 The title of the patent was Organic electroluminescent iridium complexes having three bidentate ligands. And the patent contained the following:

Methods of method of preparing a metal complex having the formula M(LA)(LB)(LC) are discussed which entail providing a precursor metal complex having the formula (LA)(LB)M-(X)2-M(LA)(LB), in which M is a metal, ligand LA and ligand LB (X = halogen; rings A-D are each independently selected from a 5-6 membered carbocyclic or heterocyclic ring; RA-RD each independently represent mono substitution up to the maximum possible number of substitutions, or no substitution; Z1-Z2 are each independently C or N; RA-RD, RX-RZ are independently selected from H, D, halide, alkyl, etc.; and where any adjacent substituents are optionally joined or fused into a ring); reacting the precursor metal complex with a first reagent to obtain the metal complex having the formula M(LA)(LB)(LC), where LC (RX-RZ are each independently selected from H, D, halide, alkyl, etc.), rings C’ and D’ are each independently selected from a 5-6 membered carbocyclic or heterocyclic ring; C1′ = anionic donor C atom; C2′ = neutral carbene C atom; RC’-RD’ are independently selected from H, D, halide, alkyl, etc., and rings A’ and B’ are each independently selected from a 5-6 membered carbocyclic or heterocyclic ring; Z1′ = anionic donor C atom; Z2′ = neutral N atom; RA’-RB’ are independently selected from H, D, halide, alkyl, etc. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).HPLC of Formula: 1349171-28-3

The Article related to organic electroluminescent iridium complex bidentate ligand, Optical, Electron, and Mass Spectroscopy and Other Related Properties: Luminescence and other aspects.HPLC of Formula: 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On January 15, 2021, Oderinde, Martins S.; Ramirez, Antonio; Dhar, T. G. Murali; Cornelius, Lyndon A. M.; Jorge, Christine; Aulakh, Darpandeep; Sandhu, Bhupinder; Pawluczyk, Joseph; Sarjeant, Amy A.; Meanwell, Nicholas A.; Mathur, Arvind; Kempson, James published an article.Recommanded Product: Methyl 5-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate The title of the article was Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity. And the article contained the following:

Indole and indoline rings are important pharmacophoric scaffolds found in marketed drugs, agrochems., and biol. active mols. The [2 + 2] cycloaddition reaction is a versatile strategy for constructing architecturally interesting, sp3-rich cyclobutane-fused scaffolds with potential applications in drug discovery programs. A general platform for visible-light mediated intermol. [2 + 2] cycloaddition of indoles with alkenes has been realized. A substrate-based screening approach led to the discovery of tert-butyloxycarbonyl (Boc)-protected indole-2-carboxyesters as suitable motifs for the intermol. [2 + 2] cycloaddition reaction. Significantly, the reaction proceeds in good yield with a wide variety of both activated and unactivated alkenes, including those containing free amines and alcs., and the transformation exhibits excellent regio- and diastereoselectivity. Moreover, the scope of the indole substrate is very broad, extending to previously unexplored azaindole heterocycles that collectively afford fused cyclobutane containing scaffolds that offer unique properties with functional handles and vectors suitable for further derivatization. DFT computational studies provide insights into the mechanism of this [2 + 2] cycloaddition, which is initiated by a triplet-triplet energy transfer process. The photocatalytic reaction was successfully performed on a 100 g scale to provide the dihydroindole analog. The experimental process involved the reaction of Methyl 5-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate(cas: 1234616-83-1).Recommanded Product: Methyl 5-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate

The Article related to regioselective diastereoselective photocatalytic dearomative intermol cycloaddition indole alkene, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Recommanded Product: Methyl 5-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On June 18, 2021, Lee, Jong Ho published a patent.Name: 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine The title of the patent was Transparent polyimide prepared using single-port synthesis. And the patent contained the following:

Title polymer is prepared by dissolving a tetracarboxylic dianhydride, a diamine, and a catalyst and it has excellent properties such as optical transparency, hydrophobicity, water absorption, dielec. constant, thermal-mech. stability, and short production time. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Name: 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine

The Article related to transparent polyimide single port tetracarboxylic dianhydride diamine catalyst, Industrial Organic Chemicals, Leather, Fats, and Waxes: Manufacture Of Industrial Organic Chemicals and other aspects.Name: 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 11, 2014, Van Gool, Michiel Luc Maria; Alonso-De Diego, Sergio-Alvar; Cid-Nunez, Jose Maria; Delgado-Gonzalez, Oscar; Decorte, Annelies Marie Antonius; Macdonald, Gregor James; Megens, Antonius Adrianus Hendrikus Petrus; Trabanco-Suarez, Andres Avelino; Garcia-Molina, Aranzazu; Andres-Gil, Jose Ignacio published a patent.Category: pyridine-derivatives The title of the patent was Preparation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mGluR2 receptors. And the patent contained the following:

Title compounds I [R1 = substituted Ph or 2-pyridinyl; R2 = substituted pyridinyl; R3 = H or alkyl; R4 = H, alkyl, mono- or polyhalo-alkyl, alkyl-O-alkyl or alkyl-OH], or a N-oxide, or a pharmaceutically acceptable salt or a solvate, are prepared as neg. allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (mGluR2). Thus, e.g., II was prepared by reaction of (7S)-methyl-3-(2-methylpyridin-4-yl)-6,7-dihydro-5H-pyrazolo[1,5-a]pyrazin-4-one with 4-bromobenzotrifluoride. Compound II showed pIC50 value of 8.05 against hmGluR2 in GTPγS binding assay. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved, especially CNS disorders. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Category: pyridine-derivatives

The Article related to dihydropyrazolopyrazine preparation neg allosteric mglur2 receptors cns disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: pyridine-derivatives

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 1, 2020, Zhou, Xiaocong; He, Xinyi; Yan, Puzha; Li, Yuanqiang published a patent.Recommanded Product: 908267-63-0 The title of the patent was Trifluoromethylation of dimethyl substituted heterocyclic compounds. And the patent contained the following:

The invention relates to the trifluoromethylation of di-Me substituted heterocyclic compounds, and has the advantage of wide range of substrate selection. For example, 2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridine was prepared by trifluoromethylation of 2-isopropyridine and 5-(trifluoromethyl)-5H-dibenzo[b,d]thiophen-5-ium trifluoromethanesulfonate. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Recommanded Product: 908267-63-0

The Article related to trifluoromethylation preparation pyrimidine quinoxaline quinazoline pyrazine, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Recommanded Product: 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On October 13, 2009, Dorsey, Bruce D.; Milkiewicz, Karen L.; Pippin, Douglas A.; Theroff, Jay P.; Underiner, Ted; Weinberg, Linda; Zificsak, Craig A. published a patent.Name: 3-((6-Bromopyridin-2-yl)amino)propanoic acid The title of the patent was Preparation of pyridopyrazine derivatives as ALK and c-Met inhibitors. And the patent contained the following:

Title compounds I [ A = N or CH; X = -L2G1L3G2L4R7 or R8, wherein G1 and G2 independently = bond, (un)substituted (hetero)aryl or heterocycloalkyl; R7 = (un)substituted alkyl, alkenyl, alkynyl, (hetero)aryl or (hetero)cycloalkyl; R8 = H, halo, CN or CO2H; L1-4 independently = bond, alkyl-C(O)-alkyl, alkyl-C(O)O-alkyl, alkyl-O-alkyl, alkyl, alkenyl, alkynyl, etc.; R1 = (un)substituted (hetero)cycloalkyl or (hetero)aryl; R2 and R3 independently = H, OH or alkyl; R2 and R3 together may form a carbonyl group; R4, R5 and R6 independently = H or alkyl; R4 and R5 together may form a carbonyl group, or one of R4 and R5 forms a double bond with R6], and their pharmaceutically acceptable salts, are prepared and disclosed as Anaplastic Lymphoma Kinase (ALK) and c-Met inhibitors. Thus, e.g., II was prepared by acylation of 7-iodo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine (preparation given) with benzoyl chloride followed by Suzuki coupling reaction with (4-ethoxycarbonylphenyl)boronic acid to generate intermediate 4-(1-benzyl-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-yl)benzoic acid Et ester followed by hydrolysis and amidation with (S)-(+)-1-[(2-pyrrolidinyl)methyl]pyrrolidine to provide II as trifluoroacetate salt. All exemplar compounds were tested for their ability to inhibit the kinase activity for ALK and c-Met. For instance, II exhibited IC50 values ranging from 0.1 to 1 μM for ALK and c-Met kinase inhibition, resp. As inhibitors of ALK and/or c-Met, I may be used to treat ALK- or c-Met-mediated disorders or conditions. The experimental process involved the reaction of 3-((6-Bromopyridin-2-yl)amino)propanoic acid(cas: 68638-67-5).Name: 3-((6-Bromopyridin-2-yl)amino)propanoic acid

The Article related to pyridopyrazine preparation anaplastic lymphoma kinase alk cmet inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Name: 3-((6-Bromopyridin-2-yl)amino)propanoic acid

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On November 15, 2007, Dorsey, Bruce D.; Milkiewicz, Karen L.; Pippin, Douglas A.; Theroff, Jay P.; Underiner, Theodore L.; Weinberg, Linda; Zificsak, Craig A. published a patent.Formula: C8H9BrN2O2 The title of the patent was Preparation of pyridopyrazine derivatives as ALK and c-Met inhibitors. And the patent contained the following:

Title compounds I [ A = N or CH; X = -L2G1L3G2L4R7 or R8, wherein G1 and G2 independently = bond, (un)substituted (hetero)aryl or heterocycloalkyl; R7 = (un)substituted alkyl, alkenyl, alkynyl, (hetero)aryl or (hetero)cycloalkyl; R8 = H, halo, CN or CO2H; L1-4 independently = bond, alkyl-C(O)-alkyl, alkyl-C(O)O-alkyl, alkyl-O-alkyl, alkyl, alkenyl, alkynyl, etc.; R1 = (un)substituted (hetero)cycloalkyl or (hetero)aryl; R2 and R3 independently = H, OH or alkyl; R2 and R3 together may form a carbonyl group; R4, R5 and R6 independently = H or alkyl; R4 and R5 together may form a carbonyl group, or one of R4 and R5 forms a double bond with R6], and their pharmaceutically acceptable salts, are prepared and disclosed as Anaplastic Lymphoma Kinase (ALK) and c-Met inhibitors. Thus, e.g., II was prepared by acylation of 7-iodo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine (preparation given) with benzoyl chloride followed by Suzuki coupling reaction with (4-ethoxycarbonylphenyl)boronic acid to generate intermediate 4-(1-benzyl-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-yl)benzoic acid Et ester followed by hydrolysis and amidation with (S)-(+)-1-[(2-pyrrolidinyl)methyl]pyrrolidine to provide II as trifluoroacetate salt. All exemplar compounds were tested for their ability to inhibit the kinase activity for ALK and c-Met. For instance, II exhibited IC50 values ranging from 0.1 to 1 μM for ALK and c-Met kinase inhibition, resp. As inhibitors of ALK and/or c-Met, I may be used to treat ALK- or c-Met-mediated disorders or conditions. The experimental process involved the reaction of 3-((6-Bromopyridin-2-yl)amino)propanoic acid(cas: 68638-67-5).Formula: C8H9BrN2O2

The Article related to pyridopyrazine preparation anaplastic lymphoma kinase alk cmet inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Formula: C8H9BrN2O2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem